Redirected optimized cell killing (ROCK®): A highly versatile multispecific fit-for-purpose antibody platform for engaging innate immunity

References

• Dahlen E, Veitonmaki N, Norlen P. Bispecific antibodies in cancer immunotherapy. Ther Adv Vaccines Immunother. 2018;6:3–17. doi:10.1177/2515135518763280.
   PubMedGoogle Scholar
• Reusch U, Burkhardt C, Fucek I, Le Gall F, Le Gall M, Hoffmann K, Knackmuss SH, Kiprijanov S, Little M, Zhukovsky EA. A novel tetravalent bispecific TandAb (CD30/CD16A) efficiently recruits NK cells for the lysis of CD30+ tumor cells. MAbs. 2014;6:728–39. doi:10.4161/mabs.28591.
   PubMed Web of Science ®Google Scholar
• Rothe A, Sasse S, Topp MS, Eichenauer DA, Hummel H, Reiners KS, Dietlein M, Kuhnert G, Kessler J, Buerkle C, et al. A phase 1 study of the bispecific anti-CD30/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma. Blood. 2015;125:4024–31. doi:10.1182/blood-2014-12-614636.
   PubMed Web of Science ®Google Scholar
• Berrien-Elliott MM, Romee R, Fehniger TA. Improving natural killer cell cancer immunotherapy. Curr Opin Organ Transplant. 2015;20:671–80. doi:10.1097/MOT.0000000000000243.
   PubMed Web of Science ®Google Scholar
• Romee R, Rosario M, Berrien-Elliott MM, Wagner JA, Jewell BA, Schappe T, Helman LJ, Kastan MB, Knapp DW, Levin WJ, et al. Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia. Sci Transl Med. 2016;8:357ra123. doi:10.1126/scitranslmed.aaf0746.
   PubMed Web of Science ®Google Scholar
• Fehniger TA, Miller JS, Stuart RK, Cooley S, Salhotra A, Curtsinger J, Westervelt P, DiPersio JF, Hillman TM, Silver N, et al. A Phase 1 Trial of CNDO-109-Activated Natural Killer Cells in Patients with High-Risk Acute Myeloid Leukemia. Biol Blood Marrow Transplant. 2018;24:1581–89. doi:10.1016/j.bbmt.2018.03.019.
   PubMed Web of Science ®Google Scholar
• Shah N, Li L, McCarty J, Kaur I, Yvon E, Shaim H, Muftuoglu M, Liu E, Orlowski RZ, Cooper L, et al. Phase I study of cord blood-derived natural killer cells combined with autologous stem cell transplantation in multiple myeloma. Br J Haematol. 2017;177:457–66. doi:10.1111/bjh.14570.
   PubMed Web of Science ®Google Scholar
• Lanier LL. NK cell recognition. Annu Rev Immunol. 2005;23:225–74. doi:10.1146/annurev.immunol.23.021704.115526.
   PubMed Web of Science ®Google Scholar
• Koch J, Tesar M. Recombinant Antibodies to Arm Cytotoxic Lymphocytes in Cancer Immunotherapy. Transfus Med Hemother. 2017;44:337–50. doi:10.1159/000479981.
   PubMed Web of Science ®Google Scholar
• Smyth MJ, Crowe NY, Godfrey DI. NK cells and NKT cells collaborate in host protection from methylcholanthrene-induced fibrosarcoma. Int Immunol. 2001;13:459–63.
   PubMed Web of Science ®Google Scholar
• Haliotis T, Ball JK, Dexter D, Roder JC. Spontaneous and induced primary oncogenesis in natural killer (NK)-cell-deficient beige mutant mice. Int J Cancer. 1985;35:505–13. doi:10.1002/(ISSN)1097-0215.
   PubMed Web of Science ®Google Scholar
• Talmadge JE, Meyers KM, Prieur DJ, Starkey JR. Role of NK cells in tumour growth and metastasis in beige mice. Nature. 1980;284:622–24. doi:10.1038/284622a0.
   PubMed Web of Science ®Google Scholar
• Good RA. Relations between immunity and malignancy. Proc Natl Acad Sci U S A. 1972;69:1026–32. doi:10.1073/pnas.69.4.1026.
   PubMed Web of Science ®Google Scholar
• Semeraro M, Rusakiewicz S, Minard-Colin V, Delahaye NF, Enot D, Vely F, Marabelle A, Papoular B, Piperoglou C, Ponzoni M, et al. Clinical impact of the NKp30/B7-H6 axis in high-risk neuroblastoma patients. Sci Transl Med. 2015;7:283ra55. doi:10.1126/scitranslmed.aad3106.
   PubMed Web of Science ®Google Scholar
• Cichocki F, Cooley S, Davis Z, DeFor TE, Schlums H, Zhang B, Brunstein CG, Blazar BR, Wagner J, Diamond DJ, et al. CD56dimCD57+NKG2C+ NK cell expansion is associated with reduced leukemia relapse after reduced intensity HCT. Leukemia. 2016;30:456–63. doi:10.1038/leu.2015.260.
   PubMed Web of Science ®Google Scholar
• Imai K, Matsuyama S, Miyake S, Suga K, Nakachi K. Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: an 11-year follow-up study of a general population. Lancet. 2000;356:1795–99. doi:10.1016/S0140-6736(00)03231-1.
   PubMed Web of Science ®Google Scholar
• Xu B, Chen L, Li J, Zheng X, Shi L, Wu C,Jiang J. Prognostic value of tumor infiltrating NK cells and macrophages in stage II+III esophageal cancer patients. Oncotarget. 2016;7:74904–16. doi:10.18632/oncotarget.12484.
   PubMedGoogle Scholar
• Versluis MAC, Marchal S, Plat A, de Bock GH, van Hall T, de Bruyn M, Hollema H, Nijman HW. The prognostic benefit of tumour-infiltrating Natural Killer cells in endometrial cancer is dependent on concurrent overexpression of Human Leucocyte Antigen-E in the tumour microenvironment. Eur J Cancer. 2017;86:285–95. doi:10.1016/j.ejca.2017.09.008.
   PubMed Web of Science ®Google Scholar
• Ishigami S, Natsugoe S, Tokuda K, Nakajo A, Che X, Iwashige H, Aridome K, Hokita S, Aikou T. Prognostic value of intratumoral natural killer cells in gastric carcinoma. Cancer. 2000;88:577–83.
   PubMed Web of Science ®Google Scholar
• Sconocchia G, Eppenberger S, Spagnoli GC, Tornillo L, Droeser R, Caratelli S, Ferrelli F, Coppola A, Arriga R, Lauro D, et al. NK cells and T cells cooperate during the clinical course of colorectal cancer. Oncoimmunology. 2014;3:e952197. doi:10.4161/21624011.2014.952197.
   PubMed Web of Science ®Google Scholar
• Sconocchia G, Zlobec I, Lugli A, Calabrese D, Iezzi G, Karamitopoulou E, Patsouris ES, Peros G, Horcic M, Tornillo L, et al. Tumor infiltration by FcgammaRIII (CD16)+ myeloid cells is associated with improved survival in patients with colorectal carcinoma. Int J Cancer. 2011;128:2663–72. doi:10.1002/ijc.25609.
   PubMed Web of Science ®Google Scholar
• Luna JI, Grossenbacher SK, Murphy WJ, Canter RJ. Targeting Cancer Stem Cells with Natural Killer Cell Immunotherapy. Expert Opin Biol Ther. 2017;17:313–24. doi:10.1080/14712598.2017.1271874.
   PubMed Web of Science ®Google Scholar
• Lazar GA, Dang W, Karki S, Vafa O, Peng JS, Hyun L, Chan C, Chung HS, Eivazi A, Yoder SC, et al. Engineered antibody Fc variants with enhanced effector function. Proc Natl Acad Sci U S A. 2006;103:4005–10. doi:10.1073/pnas.0508123103.
   PubMed Web of Science ®Google Scholar
• Umana P, Jean-Mairet J, Moudry R, Amstutz H, Bailey JE. Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity. Nat Biotechnol. 1999;17:176–80. doi:10.1038/6179.
   PubMed Web of Science ®Google Scholar
• Shields RL, Lai J, Keck R, O’Connell LY, Hong K, Meng YG, Weikert SHA, Presta LG. Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity. J Biol Chem. 2002;277:26733–40. doi:10.1074/jbc.M202069200.
   PubMed Web of Science ®Google Scholar
• Yamane-Ohnuki N, Kinoshita S, Inoue-Urakubo M, Kusunoki M, Iida S, Nakano R, Wakitani M, Niwa R, Sakurada M, Uchida K, et al. Establishment of FUT8 knockout Chinese hamster ovary cells: an ideal host cell line for producing completely defucosylated antibodies with enhanced antibody-dependent cellular cytotoxicity. Biotechnol Bioeng. 2004;87:614–22. doi:10.1002/bit.20151.
   PubMed Web of Science ®Google Scholar
• Weng WK, Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol. 2003;21:3940–47. doi:10.1200/JCO.2003.05.013.
   PubMed Web of Science ®Google Scholar
• Hamaguchi Y, Xiu Y, Komura K, Nimmerjahn F, Tedder TF. Antibody isotype-specific engagement of Fcgamma receptors regulates B lymphocyte depletion during CD20 immunotherapy. J Exp Med. 2006;203:743–53. doi:10.1084/jem.20052283.
   PubMed Web of Science ®Google Scholar
• Gerdes CA, Nicolini VG, Herter S, van Puijenbroek E, Lang S, Roemmele M, Moessner E, Freytag O, Friess T, Ries CH, et al. GA201 (RG7160): a novel, humanized, glycoengineered anti-EGFR antibody with enhanced ADCC and superior in vivo efficacy compared with cetuximab. Clin Cancer Res. 2013;19:1126–38. doi:10.1158/1078-0432.CCR-12-0989.
   PubMed Web of Science ®Google Scholar
• Byrd JC, Flynn JM, Kipps TJ, Boxer M, Kolibaba KS, Carlile DJ, Fingerle-Rowson G, Tyson N, Hirata J, Sharman JP. Randomized phase 2 study of obinutuzumab monotherapy in symptomatic, previously untreated chronic lymphocytic leukemia. Blood. 2016;127:79–86. doi:10.1182/blood-2015-03-634394.
   PubMed Web of Science ®Google Scholar
• Temam S, Spicer J, Farzaneh F, Soria JC, Oppenheim D, McGurk M, Hollebecque A, Sarini J, Hussain K, Soehrman Brossard S, et al. An exploratory, open-label, randomized, multicenter study to investigate the pharmacodynamics of a glycoengineered antibody (imgatuzumab) and cetuximab in patients with operable head and neck squamous cell carcinoma. Ann Oncol. 2017;28:2827–35. doi:10.1093/annonc/mdx489.
   PubMed Web of Science ®Google Scholar
• Cartron G, Dacheux L, Salles G, Solal-Celigny P, Bardos P, Colombat P, Watier H. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood. 2002;99:754–58.
   PubMed Web of Science ®Google Scholar
• Vallera DA, Felices M, McElmurry RT, McCullar V, Zhou X, Schmohl J, Zhang B, Lenvik AJ, Panoskaltsis-Mortari A, Verneris MR, et al. IL15 Trispecific Killer Engagers (TriKE) Make Natural Killer Cells Specific to CD33 + Targets While Also Inducing Persistence, In Vivo Expansion, and Enhanced Function. Clin Cancer Res. 2016;22:3440–50. doi:10.1158/1078-0432.CCR-15-2710.
   PubMed Web of Science ®Google Scholar
• de Palazzo I, Gercel-Taylor C, Kitson J, Weiner LM. Potentiation of tumor lysis by a bispecific antibody that binds to CA19-9 antigen and the Fc gamma receptor expressed by human large granular lymphocytes. Cancer Res. 1990;50:7123–28.
   PubMed Web of Science ®Google Scholar
• Arndt MA, Krauss J, Kipriyanov SM, Pfreundschuh M, Little M. A bispecific diabody that mediates natural killer cell cytotoxicity against xenotransplantated human Hodgkin’s tumors. Blood. 1999;94:2562–68.
   PubMed Web of Science ®Google Scholar
• Li W, Yang H, Dimitrov DS. Identification of high-affinity anti-CD16A allotype-independent human antibody domains. Exp Mol Pathol. 2016;101:281–89. doi:10.1016/j.yexmp.2016.10.001.
   PubMed Web of Science ®Google Scholar
• Brinkmann U, Kontermann RE. The making of bispecific antibodies. MAbs. 2017;9:182–212. doi:10.1080/19420862.2016.1268307.
   PubMed Web of Science ®Google Scholar
• Spiess C, Zhai Q, Carter PJ. Alternative molecular formats and therapeutic applications for bispecific antibodies. Mol Immunol. 2015;67:95–106. doi:10.1016/j.molimm.2015.01.003.
   PubMed Web of Science ®Google Scholar
• Chen S, Li J, Li Q, Wang Z. Bispecific antibodies in cancer immunotherapy. Hum Vaccin Immunother. 2016;12:2491–500. doi:10.1080/21645515.2016.1187802.
   PubMed Web of Science ®Google Scholar
• Weiskopf K, Weissman IL. Macrophages are critical effectors of antibody therapies for cancer. MAbs. 2015;7:303–10. doi:10.1080/19420862.2015.1011450.
   PubMed Web of Science ®Google Scholar
• Casneuf T, Xu XS, Adams HC, Axel AE, Chiu C, Khan I, Ahmadi T, Yan X, Lonial S, Plesner T, et al. Effects of daratumumab on natural killer cells and impact on clinical outcomes in relapsed or refractory multiple myeloma. Blood Advances. 2017;1:2105–14. doi:10.1182/bloodadvances.2017006866.
   PubMed Web of Science ®Google Scholar
• de Palazzo IG, Holmes M, Gercel-Taylor C, Weiner LM. Antitumor effects of a bispecific antibody targeting CA19-9 antigen and CD16. Cancer Res. 1992;52:5713–19.
   PubMed Web of Science ®Google Scholar
• Michallet M, Chapuis-Cellier C, Dejoie T, Lombard C, Caillon H, Sobh M, Moreau P, Attal M, Avet-Loiseau H. Heavy+light chain monitoring correlates with clinical outcome in multiple myeloma patients. Leukemia. 2018;32:376–382. doi:10.1038/leu.2017.209.
   PubMed Web of Science ®Google Scholar
• Mahaweni NM, Olieslagers TI, Rivas IO, Molenbroeck SJJ, Groeneweg M, Bos GMJ, Tilanus MGJ, Voorter CEM, Wieten L. A comprehensive overview of FCGR3A gene variability by full-length gene sequencing including the identification of V158F polymorphism. Sci Rep. 2018;8:15983. doi:10.1038/s41598-018-34258-1.
   PubMed Web of Science ®Google Scholar
• Bowles JA, Wang S-Y, Link BK, Allan B, Beuerlein G, Campbell M-A, Marquis D, Ondek B, Wooldridge JE, Smith BJ, et al. Anti-CD20 monoclonal antibody with enhanced affinity for CD16 activates NK cells at lower concentrations and more effectively than rituximab. Blood. 2006;108:2648–54. doi:10.1182/blood-2006-04-020057.
   PubMed Web of Science ®Google Scholar
• Burchard PR, Malhotra S, Kaur P, Tsongalis GJ. Detection of the FCGR3a polymorphism using a real-time polymerase chain reaction assay. Cancer Genet. 2013;206:130–34. doi:10.1016/j.cancergen.2013.03.002.
   PubMed Web of Science ®Google Scholar
• Tamm A, Schmidt RE. The binding epitopes of human CD16 (Fc gamma RIII) monoclonal antibodies. Implications for Ligand Binding. The Journal of Immunology. 1996;157:1576–81.
   PubMed Web of Science ®Google Scholar
• Vidarsson G, Dekkers G, Rispens T. IgG subclasses and allotypes: from structure to effector functions. Front Immunol. 2014;5:520. doi:10.3389/fimmu.2014.00520.
   PubMed Web of Science ®Google Scholar
• Baudino L, Shinohara Y, Nimmerjahn F, Furukawa J, Nakata M, Martinez-Soria E, Petry F, Ravetch JV, Nishimura S-I, Izui S. Crucial role of aspartic acid at position 265 in the CH2 domain for murine IgG2a and IgG2b Fc-associated effector functions. J Immunol. 2008;181:6664–69.
   PubMed Web of Science ®Google Scholar
• Hezareh M, Hessell AJ, Jensen RC, van de Winkel JG, Parren PW. Effector function activities of a panel of mutants of a broadly neutralizing antibody against human immunodeficiency virus type 1. J Virol. 2001;75:12161–68. doi:10.1128/JVI.75.24.12161-12168.2001.
   PubMed Web of Science ®Google Scholar
• Ahmed AA, Keremane SR, Vielmetter J, Bjorkman PJ. Structural characterization of GASDALIE Fc bound to the activating Fc receptor FcgammaRIIIa. J Struct Biol. 2016;194:78–89. doi:10.1016/j.jsb.2016.02.001.
   PubMed Web of Science ®Google Scholar
• Merchant M, Ma X, Maun HR, Zheng Z, Peng J, Romero M, Huang A, Yang N-Y, Nishimura M, Greve J, et al. Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent. Proc Natl Acad Sci U S A. 2013;110:E2987–96. doi:10.1073/pnas.1302725110.
   PubMed Web of Science ®Google Scholar
• McAleese F, Eser M. RECRUIT-TandAbs: harnessing the immune system to kill cancer cells. Future Oncol. 2012;8:687–95. doi:10.2217/fon.12.54.
   PubMed Web of Science ®Google Scholar
• Gantke T, Weichel M, Herbrecht C, Reusch U, Ellwanger K, Fucek I, Eser M, Müller T, Griep R, Molkenthin V, et al. Trispecific antibodies for CD16A-directed NK cell engagement and dual-targeting of tumor cells. Protein Eng Des Sel. 2017;30:673–84. doi:10.1093/protein/gzx043.
   PubMed Web of Science ®Google Scholar
• Reusch U, Duell J, Ellwanger K, Herbrecht C, Knackmuss SH, Fucek I, Eser M, McAleese F, Molkenthin V, Gall FL, et al. A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells. MAbs. 2015;7:584–604. doi:10.1080/19420862.2015.1029216.
   PubMed Web of Science ®Google Scholar
• Ellwanger K, Reusch U, Fucek I, Knackmuss S, Weichel M, Gantke T, Molkenthin V, Zhukovsky EA, Tesar M, Treder M. Highly Specific and Effective Targeting of EGFRvIII-Positive Tumors with TandAb Antibodies. Front Oncol. 2017;7:100. doi:10.3389/fonc.2017.00100.
   Google Scholar
• Reusch U, Harrington KH, Gudgeon CJ, Fucek I, Ellwanger K, Weichel M, Knackmuss SHJ, Zhukovsky EA, Fox JA, Kunkel LA, et al. Characterization of CD33/CD3 Tetravalent Bispecific Tandem Diabodies (TandAbs) for the Treatment of Acute Myeloid Leukemia. Clin Cancer Res. 2016;22:5829–38. doi:10.1158/1078-0432.CCR-16-0350.
   PubMed Web of Science ®Google Scholar
• Ridgway JB, Presta LG, Carter P. ‘Knobs-into-holes’ engineering of antibody CH3 domains for heavy chain heterodimerization. Protein Eng. 1996;9:617–21.
   PubMedGoogle Scholar
• Ying T, Chen W, Gong R, Feng Y, Dimitrov DS. Soluble monomeric IgG1 Fc. J Biol Chem. 2012;287:19399–408. doi:10.1074/jbc.M112.368647.
   PubMed Web of Science ®Google Scholar
• Coloma MJ, Morrison SL. Design and production of novel tetravalent bispecific antibodies. Nat Biotechnol. 1997;15:159–63. doi:10.1038/nbt0297-159.
   PubMed Web of Science ®Google Scholar
• Choi EI, Wang R, Peterson L, Letvin NL, Reimann KA. Use of an anti-CD16 antibody for in vivo depletion of natural killer cells in rhesus macaques. Immunology. 2008;124:215–22. doi:10.1111/j.1365-2567.2007.02757.x.
   PubMed Web of Science ®Google Scholar
• Unverdorben F, Richter F, Hutt M, Seifert O, Malinge P, Fischer N, Kontermann RE. Pharmacokinetic properties of IgG and various Fc fusion proteins in mice. MAbs. 2016;8:120–28. doi:10.1080/19420862.2015.1113360.
   PubMed Web of Science ®Google Scholar
• Jacobi C, Claus M, Wildemann B, Wingert S, Korporal M, Römisch J, Meuer S, Watzl C, Giese T. Exposure of NK cells to intravenous immunoglobulin induces IFN gamma release and degranulation but inhibits their cytotoxic activity. Clin Immunol. 2009;133:393–401. doi:10.1016/j.clim.2009.09.006.
   PubMed Web of Science ®Google Scholar
• Rudin CM, Pietanza MC, Bauer TM, Ready N, Morgensztern D, Glisson BS, Byers LA, Johnson ML, Burris HA, Robert F, et al. Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study. Lancet Oncol. 2017;18:42–51. doi:10.1016/S1470-2045(16)30565-4.
   PubMed Web of Science ®Google Scholar
• Circosta P, Elia AR, Landra I, Machiorlatti R, Todaro M, Aliberti S, Hoadley KA, Print C, Knowlton N, Black MA, et al. Tailoring CD19xCD3-DART exposure enhances T-cells to eradication of B-cell neoplasms. Oncoimmunology. 2018;7:e1341032. doi:10.1080/2162402X.2018.1490854.
   PubMed Web of Science ®Google Scholar
• Sedykh SE, Prinz VV, Buneva VN, Nevinsky GA. Bispecific antibodies: design, therapy, perspectives. Drug Des Devel Ther. 2018;12:195–208. doi:10.2147/DDDT.S151282.
   PubMed Web of Science ®Google Scholar
• Scott AM, Wolchok JD, Old LJ. Antibody therapy of cancer. Nat Rev Cancer. 2012;12:278–87. doi:10.1038/nrc3236.
   PubMed Web of Science ®Google Scholar
• Tang X, Yang L, Li Z, Nalin AP, Dai H, Xu T, Yin J, You F, Zhu M, Shen W. First-in-man clinical trial of CAR NK-92 cells: safety test of CD33-CAR NK-92 cells in patients with relapsed and refractory acute myeloid leukemia. Am J Cancer Res. 2018;8:1083.
   PubMed Web of Science ®Google Scholar
• Coca S, Perez-Piqueras J, Martinez D, Colmenarejo A, Saez MA, Vallejo C, Martos JA, Moreno M. The prognostic significance of intratumoral natural killer cells in patients with colorectal carcinoma. Cancer. 1997;79:2320–28.
   PubMed Web of Science ®Google Scholar
• Marechal R, De Schutter J, Nagy N, Demetter P, Lemmers A, Deviere J, Salmon I, Tejpar S, Van Laethem JL. Putative contribution of CD56 positive cells in cetuximab treatment efficacy in first-line metastatic colorectal cancer patients. BMC Cancer. 2010;10:340. doi:10.1186/1471-2407-10-663.
   PubMed Web of Science ®Google Scholar
• Villegas FR, Coca S, Villarrubia VG, Jiménez R, MaJ C, Jareño J, Zuil M, Callol L. Prognostic significance of tumor infiltrating natural killer cells subset CD57 in patients with squamous cell lung cancer. Lung Cancer. 2002;35:23–28.
   PubMed Web of Science ®Google Scholar
• Reiners KS, Kessler J, Sauer M, Rothe A, Hansen HP, Reusch U, Hucke C, Köhl U, Dürkop H, Engert A, et al. Rescue of impaired NK cell activity in hodgkin lymphoma with bispecific antibodies in vitro and in patients. Mol Ther. 2013;21:895–903.
   PubMed Web of Science ®Google Scholar
• Lanier LL, Ruitenberg JJ, Phillips JH. Functional and biochemical analysis of CD16 antigen on natural killer cells and granulocytes. J Immunol. 1988;141:3478–85.
   PubMed Web of Science ®Google Scholar
• Koene HR, Kleijer M, Algra J, Roos D, Ae VDB, de Haas M. Fc gammaRIIIa-158V/F polymorphism influences the binding of IgG by natural killer cell Fc gammaRIIIa, independently of the Fc gammaRIIIa-48L/R/H phenotype. Blood. 1997;90:1109–14.
   PubMed Web of Science ®Google Scholar
• Wu J, Edberg JC, Redecha PB, Bansal V, Guyre PM, Coleman K, Salmon JE, Kimberly RP. A novel polymorphism of FcgammaRIIIa (CD16) alters receptor function and predisposes to autoimmune disease. J Clin Invest. 1997;100:1059–70. doi:10.1172/JCI119616.
   PubMed Web of Science ®Google Scholar
• Pazina T, James AM, AWt M, Bezman NA, Henning KA, Bee C, Graziano RF, Robbins MD, Cohen AD, Campbell KS. The anti-SLAMF7 antibody elotuzumab mediates NK cell activation through both CD16-dependent and -independent mechanisms. Oncoimmunology. 2017;6:e1339853. doi:10.1080/2162402X.2017.1339853.
   PubMed Web of Science ®Google Scholar
• Heider K-H, Kiefer K, Zenz T, Volden M, Stilgenbauer S, Ostermann E, Baum A, Lamche H, Küpcü Z, Jacobi A, et al. A novel Fc-engineered monoclonal antibody to CD37 with enhanced ADCC and high proapoptotic activity for treatment of B-cell malignancies. Blood. 2011;118:4159–68. doi:10.1182/blood-2011-04-351932.
   PubMed Web of Science ®Google Scholar
• Treffers LW, Hiemstra IH, Kuijpers TW, TKvd B, Matlung HL. Neutrophils in cancer. Immunol Rev. 2016; 273:312–28.
   Google Scholar
• Treffers LW, van Houdt M, Bruggeman CW, Heineke MH, Zhao XW, van der Heijden J, Nagelkerke SQ, Verkuijlen P, Geissler J, Lissenberg-Thunnissen S, et al. FcgammaRIIIb Restricts Antibody-Dependent Destruction of Cancer Cells by Human Neutrophils. Front Immunol. 2018;9:3124. doi:10.3389/fimmu.2018.03124.
   PubMed Web of Science ®Google Scholar
• Kontermann RE, Brinkmann U. Bispecific antibodies. Drug Discov Today. 2015;20:838–47. doi:10.1016/j.drudis.2015.02.008.
   PubMed Web of Science ®Google Scholar
• Schoonjans R, Willems A, Schoonooghe S, Fiers W, Grooten J, Mertens N. Fab Chains As an Efficient Heterodimerization Scaffold for the Production of Recombinant Bispecific and Trispecific Antibody Derivatives. J Immunol. 2000;165:7050–57.
   PubMed Web of Science ®Google Scholar
• Schoonjans R, Willems A, Schoonooghe S, Leoen J, Grooten J, Mertens N. A new model for intermediate molecular weight recombinant bispecific and trispecific antibodies by efficient heterodimerization of single chain variable domains through fusion to a Fab-chain. Biomol Eng. 2001;17:193–202.
   PubMedGoogle Scholar
• Schmohl JU, Felices M, Oh F, Lenvik AJ, Lebeau AM, Panyam J, Miller JS, Vallera DA. Engineering of Anti-CD133 Tri-Specific Molecule Capable of Inducing NK Expansion and Driving Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC). Cancer Res Treat. 2017;49:1140–52. doi:10.4143/crt.2016.491.
   PubMed Web of Science ®Google Scholar
• Schmohl JU, Gleason MK, Dougherty PR, Miller JS, Vallera DA. Heterodimeric Bispecific Single Chain Variable Fragments (scFv) Killer Engagers (BiKEs) Enhance NK-cell Activity Against CD133+ Colorectal Cancer Cells. Target Oncol. 2016;11:353–61. doi:10.1007/s11523-015-0391-8.
   PubMed Web of Science ®Google Scholar
• Baeuerle PA, Reinhardt C. Bispecific T-cell engaging antibodies for cancer therapy. Cancer Res. 2009;69:4941–44. doi:10.1158/0008-5472.CAN-09-0547.
   PubMed Web of Science ®Google Scholar
• Löffler A, Kufer P, Lutterbüse R, Zettl F, Daniel PT, Schwenkenbecher JM, Riethmüller G, Dörken B, Bargou RC. A recombinant bispecific single-chain antibody, CD19 x CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes. Blood. 2000;95:2098–103.
   PubMed Web of Science ®Google Scholar
• Rader C. DARTs take aim at BiTEs. Blood. 2011;117:4403–04. doi:10.1182/blood-2011-02-337691.
   PubMed Web of Science ®Google Scholar
• Holliger P, Prospero T, Winter G. “Diabodies”: small bivalent and bispecific antibody fragments. Proc Natl Acad Sci U S A. 1993;90:6444–48. doi:10.1073/pnas.90.14.6444.
   PubMed Web of Science ®Google Scholar
• Perisic O, Webb PA, Holliger P, Winter G, Williams RL. Crystal structure of a diabody, a bivalent antibody fragment. Structure. 1994;2:1217–26.
   PubMed Web of Science ®Google Scholar
• Kim JH, Song DH, Youn S-J, Kim JW, Cho G, Kim SC, Lee H, Jin MS, Lee J-O. Crystal structures of mono- and bi-specific diabodies and reduction of their structural flexibility by introduction of disulfide bridges at the Fv interface. Sci Rep. 2016;6:34515. doi:10.1038/srep34515.
   PubMed Web of Science ®Google Scholar
• Carmichael JA, Power BE, Garrett TPJ, Yazaki PJ, Shively JE, Raubischek AA,Wu AM, Hudson PJ. The Crystal Structure of an Anti-CEA scFv Diabody Assembled from T84.66 scFvs in VL-to-VH Orientation: implications for Diabody Flexibility. J Mol Biol. 2003;326:341–51.
   Google Scholar
• Wang Y, Zhang Y, Hughes T, Zhang J, Caligiuri MA, Benson DM, Yu J. Fratricide of NK Cells in Daratumumab Therapy for Multiple Myeloma Overcome by Ex Vivo-Expanded Autologous NK Cells. Clin Cancer Res. 2018;24:4006–17. doi:10.1158/1078-0432.CCR-17-3117.
   PubMed Web of Science ®Google Scholar
• Todorovska A, Roovers RC, Dolezal O, Kortt AA, Hoogenboom HR, Hudson PJ. Design and application of diabodies, triabodies and tetrabodies for cancer targeting. J Immunol Methods. 2001;248:47–66.
   PubMed Web of Science ®Google Scholar
• Le Gall F, Reusch U, Little M, Kipriyanov SM. Effect of linker sequences between the antibody variable domains on the formation, stability and biological activity of a bispecific tandem diabody. Protein Eng Des Sel. 2004;17:357–66. doi:10.1093/protein/gzh039.
   PubMed Web of Science ®Google Scholar
• Wang X, Chang W-C, Wong CW, Colcher D, Sherman M, Ostberg JR, Forman SJ, Riddell SR, Jensen MC. A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells. Blood. 2011;118:1255–63. doi:10.1182/blood-2011-02-337360.
   PubMed Web of Science ®Google Scholar
• Fuss IJ, Kanof ME, Smith PD, Zola H. Isolation of whole mononuclear cells from peripheral blood and cord blood. Curr Protoc Immunol. 2009;85:7.1. −7.1. 8.
   Google Scholar